SCHEMBL301274

SCHEMBL301274

c1ccc(P(C2CCCC2)C2CCCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.41
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 3/20 0.34
ALDH1A1 P00352 2/20 0.34
POLB P06746 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SLC18A3 Q16572 1/20 0.31
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
IDO1 P14902 1/20 0.31
HPGD P15428 1/20 0.31
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL54719 0.98 ROCK2 (0.44) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL301161 0.98 ROCK2 (0.44) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL301129 0.98 ROCK2 (0.44) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL2271458 0.95 ROCK2 (0.43) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL9516193 0.95 ROCK2 (0.43) ROCK2CYP3A4TDP1GAAALDH1A1
Bromide SCHEMBL8849424 0.95 ROCK2 (0.43) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL30727801 0.95 ROCK2 (0.43) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL9634618 0.95 ROCK2 (0.43) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL28530861 0.95 ROCK2 (0.43) ROCK2CYP3A4TDP1GAAALDH1A1
SCHEMBL301091 0.95 CYP3A4 (0.39) ROCK2CYP3A4TDP1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688604-B2 Phosphine ligand and palladium catalysts based thereon for the alkoxycarbonylation of ethylenically unsaturated compounds EVONIK DEGUSSA GMBH (DE) 2017-06-27 US disclosed
CN-106687466-A Method for producing ethylenedialkylphosphinic acids, esters and salts, and the use thereof as flame retardants 科莱恩塑料和涂料有限公司 2017-05-17 CN disclosed
CN-103724372-B The purposes of ethylene alkyl phosphinic acid, ethylene alkyl phosphinates and ethylene alkyl phosphinate 科莱恩金融(BVI)有限公司 2017-03-01 CN disclosed
US-20170022236-A1 FERROCENE-BASED COMPOUNDS AND PALLADIUM CATALYSTS BASED THEREON FOR THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS EVONIK DEGUSSA GMBH (DE) 2017-01-26 US disclosed
US-20170022234-A1 PHOSPHINE LIGAND AND PALLADIUM CATALYSTS BASED THEREON FOR THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS EVONIK DEGUSSA GMBH (DE) 2017-01-26 US disclosed
EP-3121185-A2 PHOSPHIN LIGAND AND PALLADIUM CATALYST BASED ON SAME FOR ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS Evonik Degussa GmbH (DE) 2017-01-25 EP disclosed
EP-2610248-B1 METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND TEIJIN PHARMA LTD (JP) 2016-06-08 EP disclosed
US-9243098-B2 Compound, polymer, cross-linked compound of polymer, and optical element including cross-linked compound CANON KABUSHIKI KAISHA (JP) 2016-01-26 US disclosed
CN-102164934-B Method for producing mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts by means of ethylene oxide, and use thereof CLARIANT FINANCE (BVI) LTD. (VG) 2015-11-25 CN disclosed
CN-102186865-B Method for producing dialkylphosphinic acids, esters and salts using acrylonitrile, and use thereof CLARIANT FINANCE (BVI) LTD. (VG) 2015-10-14 CN disclosed
WO-2007035540-A2 PROCESS FOR THE MONOSULFONATION OF AROMATIC PHOSPHINES, AND ZWITTERIONIC PRODUCT DERIVED THEREFROM DOW GLOBAL TECHNOLOGIES INC. (US) 2007-03-29 WO disclosed
EP-0927577-B1 Ruthenium metathesis catalyst and method for olefin metathesis using the same TAKASAGO PERFUMERY CO LTD (JP) 2004-06-23 EP disclosed
US-6313365-B1 Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2001-11-06 US disclosed
US-6175047-B1 A CATALYST MIXTURE INCLUDING A RUTHENIUM COMPOUND, A DIHALOGENO COMPOUND, A TERMINAL ALKYNE; AS A CATALYST FOR A CARBON-CARBON BOND FORMATION REACTION TAKASAGO INTERNATIONAL CORPORATION (JP) 2001-01-16 US disclosed
EP-0696474-B1 Catalytic systems and methods for carbonylation DAICEL CHEM (JP) 2000-05-17 EP disclosed
EP-0948999-A1 Catalytic systems and method for carbonylation DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-10-13 EP disclosed
EP-0927577-A1 Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same Takasago International Corporation (JP) 1999-07-07 EP disclosed
US-5869738-A OF AN OLEFIN WITH CARBON MONOXIDE PRODUCING AN ACID DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-02-09 US disclosed
US-5731255-A GROUP VIII METAL SOURCE, LIGAND, ACID DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-24 US disclosed
EP-0696474-A2 Catalytic systems and methods for carbonylation DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022234-A1 PHOSPHINE LIGAND AND PALLADIUM CATALYSTS BASED THEREON FOR THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS PDCD1LG2, PDCD1, CD274 ROCK2 2933/4885CYP3A4 1838/4885TDP1 2787/4885
US-20170022236-A1 FERROCENE-BASED COMPOUNDS AND PALLADIUM CATALYSTS BASED THEREON FOR THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS C5, C1S, ALOX12 ROCK2 1999/4885CYP3A4 1060/4885TDP1 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.